Tumor targeting with a selective gelatinase inhibitor

Koivunen, Erkki, Arap, Wadih, Valtanen, Heli, Rainisalo, Aija, Medina, Oula Penate, Heikkilä, Pia, Kantor, Carmela, Gahmberg, Carl G., Salo, Tuula, Konttinen, Yrjö T., Sorsa, Timo, Ruoslahti, Erkki, Pasqualini, Renata·1999·Nature Biotechnology

DOI 10.1038/11703

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/11703

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche
Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., Le, Q.-T., & Giaccia, A. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.11.012 · Cited by 1,231
Angiogenesis: regulators and clinical applications
Liekens, S., De Clercq, E., & Neyts, J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00529-3 · Cited by 748
In vivo molecular target assessment of matrix metalloproteinase inhibition
Bremer, C., Tung, C.-H., & Weissleder, R. (2001) · Nature Medicine · doi:10.1038/89126 · Cited by 726
Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells
Lv, Y., Xu, C., Zhao, X., Lin, C., Yang, X., Xin, X., Zhang, L., Qin, C., Han, X., Yang, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08051 · Cited by 235
Therapeutic peptides.
Lien, S., & Lowman, H. B. (2003) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.10.005 · Cited by 209
Targeting tumor vasculature with homing peptides from phage display
Ruoslahti, E. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0334 · Cited by 157
Self-citation
Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain.
Lehti, K., Valtanen, H., Wickström, S., Lohi, J., & Keski-Oja, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910220199 · Cited by 144
Self-citation
Peptidic Biomaterials: From Self-Assembling to Regenerative Medicine
Pugliese, R., & Gelain, F. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.09.004 · Cited by 133
Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
Wang, S., Placzek, W. J., Stebbins, J. L., Mitra, S., Noberini, R., Koolpe, M., Zhang, Z., Dahl, R., Pasquale, E. B., & Pellecchia, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201743s · Cited by 94
Collagenase‐2 (MMP‐8) and matrilysin‐2 (MMP‐26) expression in human wounds of different etiologies
Pirilä, E., Korpi, J. T., Korkiamäki, T., Jahkola, T., Gutierrez‐Fernandez, A., Lopez‐Otin, C., Saarialho‐Kere, U., Salo, T., & Sorsa, T. (2007) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2006.00184.x · Cited by 92
Self-citation
Osteoprotegerin reduces the serum level of receptor activator of NF-κB ligand derived from osteoblasts.
Nakamichi, Y., Udagawa, N., Kobayashi, Y., Nakamura, M., Yamamoto, Y., Yamashita, T., Mizoguchi, T., Sato, M., Mogi, M., Penninger, J. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.192 · Cited by 50
Trypsin-2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue
Stenman, M., Ainola, M., Valmu, L., Bjartell, A., Ma, G., Stenman, U.-H., Sorsa, T., Luukkainen, R., & Konttinen, Y. T. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61200-x · Cited by 37
Self-citation
Lefty peptides, derived by MMP2 cleavage, act as a new class of gelatinase A inhibitor
Naidu, D. (2008) · Frontiers in Bioscience · doi:10.2741/3221 · Cited by 4

Authors: Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O. P., Heikkilä, P., Kantor, C., Gahmberg, C. G., Salo, T., Konttinen, Y. T., Sorsa, T., Ruoslahti, E., & Pasqualini, R.
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 1999-08
Volume: 17
Issue: 8
Pages: 768-774
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/11703
OpenAlex: W1576210721
Cited by: 567
References: 0
FWCI: 13.98
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review